10-K · March 3, 2026
Amylyx remains a clinical-stage biopharma focused on avexitide (GLP-1 receptor antagonist for PBH) and a neurodegeneration program (AMX0035, AMX0114). The company reports no meaningful product revenue (reported revenue…
Earnings analysis · 10-Q
AMLX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Amylyx Pharmaceuticals achieved a Q1 2026 net loss of $41.3 million, reflecting a negative EPS of -$0.37, beating street expectations of -$0.34. Significant R&D expenditures were noted at $27.6 million, driven primarily…
Read full summary
Amylyx Pharmaceuticals achieved a Q1 2026 net loss of $41.3 million, reflecting a negative EPS of -$0.37, beating street expectations of -$0.34. Significant R&D expenditures were noted at $27.6 million, driven primarily by avexitide clinical trials, and the firm's cash reserves stand at $279.8 million, projected to sustain operations until 2028.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.37
What stood out
-
EPS Beat Expectations
Reported EPS of -$0.37 beat estimates of -$0.34.
-
Increased R&D Expenses
R&D expenses rose to $27.6 million, up from $22.1 million YoY, primarily due to Phase 3 clinical trials.
-
Cash Reserves Extended
Cash and equivalents totaled $279.8 million, sufficient to fund operations through 2028.
-
Operating Loss Declined
Net loss of $41.3 million in Q1 2026, compared to $35.9 million in Q1 2025.
-
Improved Cash Flow from Investing
Net cash provided by investing activities was $36.3 million, a significant improvement from a $43.7 million outflow last year.
-
Strong Interest Income
Interest income for the quarter increased to $2.57 million from $2.23 million YoY.
What to watch
-
Persistent Net Loss
Net loss increased to $41.3 million compared to a $35.9 million loss in the prior year.
-
Clinical Trial Risks
Increased reliance on avexitide development could jeopardize future financial performance.
-
Cash Flow Constraints
Continued negative operating cash flow of $36.88 million may limit operational flexibility.
Management's outlook
Management anticipates cash runway sufficient through 2028 but deferred numeric guidance on future revenues.
Earlier filings 4
10-Q · November 6, 2025
Amylyx reported Q3 2025 product revenue of $0 and GAAP net loss per share of $(0.37), an improvement vs. Q3 2024. Operating loss narrowed to $(36,027) (in thousands) driven by lower operating expenses and a $256.7…
10-Q · August 7, 2025
Amylyx reported Q2 2025 GAAP net loss of $41,443 (per the condensed statements) with GAAP diluted EPS of $(0.46). Product revenue remained nil (Product revenue, net $—) while operating expenses declined to $42,857 from…
10-Q · May 8, 2025
Amylyx reported Q1 2025 GAAP net loss of $35,907,000 (EPS -$0.42), a sizable improvement versus Q1 2024 net loss of $118,793,000 (EPS -$1.75). Product revenue fell to $0 in the quarter (Q1 2024: $88,643,000) as the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.